UCLA Jonsson Comprehensive Cancer Center

University of California Los Angeles

Los Angeles, CA

Sorting 3 by

Accepting patients

AG-946

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Learn more
  • Pyruvate Kinase
  • Phase 2
  • Has results

Accepting patients

SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Learn more
  • Hypomethylating Agents (HMA)
  • RAR-α / NR1B1
  • Phase 3

Accepting patients

R289

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Learn more
  • IRAK 1 Inhibitor
  • IRAK 4 Inhibitor
  • Phase 1/2